Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriam

NEW YORK, July 07, 2023 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced...

Related Keywords

New York , United States , American , Mark Jacobson , Darren Opland , World Trade Center , A Foundation For Clinical Neuroscience , Axsome Therapeutics Inc , Corporate Communications , National Comorbidity Survey Replication , American Psychiatric Association , Drug Administration , Nasdaq , Forward Treatment , Attention Deficit , Hyperactivity Using Solriamfetol , Symptom Report Scale , Attention Deficit Hyperactivity Disorder , Axsome Therapeutics , Psychiatric Association , Statistical Manual , Mental Disorders , American Psychiatric Publishing , Psychiatry Reports , Molecular Neuropharmacology , Clinical Neuroscience , Second Edition , Mcgraw Hill Professional , Rev Dis Primers , National Comorbidity Survey , Remission From , Multimodal Treatment Study ,